The Latest Cardiac and Vascular News
MILFORD, Mass.–(BUSINESS WIRE)–RenalGuard Solutions™, Inc., a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that Howard R. Levin, M.D., has been named the company’s chief medical officer. A veteran in the field of biomedical engineering and cardiology and one of the original developers […]
SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the expansion of the company’s U.S. feasibility study to evaluate the investigational AccuCinch®Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR). Ancora has received approval from […]
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study of its investigational drug, mavacamten. MyoKardia recently completed the Phase […]
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has approved national reimbursement coverage for the CardiAMP Chronic Myocardial Ischemia Trial. “We are thankful for the CMS decision to […]
PARIS–(BUSINESS WIRE)–HighLife SAS, a medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from mitral regurgitation, announced today the appointment of Dr. Martin T. Rothman as non-executive independent member of its Board of Directors. Dr. Rothman retired recently from his position as Vice President of […]
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for patients with heart failure, today announced the appointment of Matthew Stark, Ph.D., as vice president of clinical and regulatory affairs, and Trevor Moody as the newest member of its board of directors. “We’re thrilled to […]
Supports U.S. Market Introduction of SuperSaturated Oxygen Therapy for Improved AMI Patient Outcomes Irvine, Calif., May 7, 2018 – TherOx®, a privately held medical device company focused on improving treatment of acute myocardial infarction (AMI), today announced completion of a debt financing for an undisclosed amount led by existing investor […]
NEW YORK, May 4, 2018 /PRNewswire/ — Jeffrey S. Borer, MD, is a distinguished biographee of Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are chosen from among a pool of the most prominent professionals and are selected on the basis of current reference value. Factors such as […]
SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy (NCT03458130). The Phase 2 trial will enroll […]
BARCELONA, Spain, May 2, 2018 /PRNewswire/ — NMT2 announces the further expansion of the NobleStitch™ EL with the addition of Hospitals in Barcelona, the first to perform PFO closure cases in Spain has been Vall Hebron Hospital. Dr. Gerard Marti, Consultant in Interventional Cardiology and Structural Heart disease at the Hospital Vall Hebron was the first […]
